Welcome to our dedicated page for Bioxcel Therapeutics news (Ticker: BTAI), a resource for investors and traders seeking the latest updates and insights on Bioxcel Therapeutics stock.
BioXcel Therapeutics, Inc. (BTAI) is a clinical-stage biopharmaceutical company pioneering AI-driven drug re-innovation in neuroscience and immuno-oncology. This page serves as the definitive source for official updates including clinical trial progress, regulatory milestones, and strategic initiatives.
Investors and industry observers will find curated press releases detailing advancements in BXCL501 development for neuropsychiatric conditions, immuno-oncology research through subsidiary OnkosXcel, and financial disclosures. Our news collection enables stakeholders to track how machine learning accelerates therapeutic discovery while managing development risks.
Content is organized to highlight essential updates: clinical trial results, regulatory filings, research collaborations, and financial performance. Each update reflects BioXcel's unique approach combining big data analytics with established clinical science to address unmet medical needs.
Bookmark this page for direct access to verified information about BioXcel's innovative pipeline and corporate developments. Check regularly for updates on how artificial intelligence continues to reshape therapeutic discovery in high-need medical specialties.
BioXcel Therapeutics (BTAI) reported financial results for Q2 2021, including a net loss of $27.6 million. The company raised approximately $100 million through a stock offering in June, supporting ongoing clinical studies and commercialization efforts. BXCL501, aimed at treating agitation in schizophrenia and bipolar disorders, has received an FDA PDUFA date of January 5, 2022. The Phase 3 program for dementia-related agitation is anticipated to begin in Q4 2021. R&D expenses decreased to $13.5 million, while G&A expenses rose sharply to $14.1 million due to increased team expansion costs.
BioXcel Therapeutics, Inc. (BTAI) announced the release of its second quarter 2021 financial results scheduled for August 10, 2021, before U.S. market opening. A conference call will follow at 8:30 AM EDT to discuss the results and provide a business update. The company focuses on utilizing artificial intelligence to develop innovative treatments in neuroscience and immuno-oncology, with notable clinical advancements in BXCL501 and BXCL701, aimed at addressing agitation and aggressive prostate cancer, respectively.
BioXcel Therapeutics (BTAI) will participate in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 9:30 a.m. Eastern Time. The event will feature Dr. Vimal Mehta, the CEO and Founder of BioXcel. Investors and interested parties can access the live webcast on the Company’s website under the “Events” section. A replay will be available for 30 days post-event. BioXcel focuses on utilizing artificial intelligence to develop innovative medicines, including therapies for agitation and advanced prostate cancer.
BioXcel Therapeutics (BTAI) has priced an underwritten public offering of 3,155,000 shares at $31.70 each, aiming for gross proceeds of approximately $100 million. A related party, BioXcel LLC, has granted underwriters a 30-day option to purchase up to 473,250 additional shares. The offering is set to close around June 25, 2021, and is being managed by BofA Securities under a previously filed registration statement with the SEC. The company will not receive any proceeds from shares sold by BioXcel LLC.
BioXcel Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: BTAI), has initiated a public offering of $100 million in common stock. Additionally, a related stockholder may grant underwriters a 30-day option for an extra $15 million. Proceeds will be allocated for ongoing clinical trials, commercialization preparations, and general corporate purposes. The offering is subject to market conditions, with no assurance on timing or actual terms. This is being conducted under an existing SEC registration statement.
BioXcel Therapeutics (Nasdaq: BTAI) has scheduled a virtual Commercial Day on June 25, 2021, from 12:00 PM ET to 1:30 PM ET. This event aims to update stakeholders on the launch readiness for BXCL501, an investigational treatment for agitation associated with schizophrenia and bipolar disorders. Attendees will include CEO Vimal Mehta and industry experts, offering insights into BXCL501’s market potential. The event will be available via live webcast on the company’s website and archived for 30 days.
BioXcel Therapeutics (Nasdaq: BTAI) announced that Dr. Vimal Mehta, CEO, will participate in three upcoming virtual healthcare investor conferences. These include the Jefferies Virtual Healthcare Conference on June 2, Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, and BofA Securities Napa Biopharma Conference on June 14. The live webcasts will be accessible on the Company's website and archived for 30 days post-event. BioXcel focuses on utilizing artificial intelligence to develop innovative medicines in neuroscience and immuno-oncology.
BioXcel Therapeutics has announced the FDA's acceptance of their New Drug Application for BXCL501, an investigational treatment for acute agitation associated with schizophrenia and bipolar disorders. The FDA has set a PDUFA action date for January 5, 2022. BXCL501, if approved, would be a significant advancement in treating agitation, a common and challenging symptom affecting nearly 3 million adults in the U.S. annually. The NDA is supported by positive results from two Phase 3 studies demonstrating BXCL501's efficacy and safety.
BioXcel Therapeutics (BTAI) announced the selection of four abstracts for presentation at the ISBD 2021 Global Annual Conference from May 13-15, 2021. Key topics include the pivotal SERENITY program results on BXCL501's efficacy in treating acute agitation in bipolar disorder. The company has also submitted a New Drug Application for BXCL501 to the FDA. This innovative formulation targets agitation mechanisms and has received breakthrough designations, emphasizing its potential in neuropsychiatric treatment.
BioXcel Therapeutics (BTAI) announced significant advancements regarding BXCL501, which received FDA Breakthrough Therapy designation for treating agitation related to dementia. The registrational program is expected to commence in the second half of 2021. The company submitted a New Drug Application (NDA) for BXCL501 aimed at agitation in schizophrenia and bipolar disorders. Commercial preparations are ramping up, alongside plans to file a Marketing Authorization Application (MAA) with the EMA. First quarter financials revealed a net loss of $26.4 million and R&D expenses increased to $14.7 million, reflecting growth in personnel and consulting needs.
FAQ
What is the current stock price of Bioxcel Therapeutics (BTAI)?
What is the market cap of Bioxcel Therapeutics (BTAI)?
